Insmed Incorporated (NASDAQ:INSM) Insider Sells $117,403.00 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Orlov S. Nicole Schaeffer sold 1,642 shares of Insmed stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $71.50, for a total transaction of $117,403.00. Following the transaction, the insider now directly owns 118,579 shares in the company, valued at $8,478,398.50. This trade represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Insmed Trading Up 1.2%

Shares of INSM stock opened at $73.62 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a market capitalization of $13.41 billion, a P/E ratio of -13.17 and a beta of 0.80. The company has a 50 day moving average price of $69.28 and a 200 day moving average price of $73.03. Insmed Incorporated has a fifty-two week low of $55.74 and a fifty-two week high of $84.91.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.36) by ($0.06). The business had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter last year, the firm posted ($1.06) EPS. Equities research analysts predict that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in INSM. Cullen Frost Bankers Inc. grew its holdings in shares of Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 221 shares in the last quarter. Elequin Capital LP purchased a new position in Insmed in the fourth quarter worth approximately $28,000. Steward Partners Investment Advisory LLC lifted its stake in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 163 shares during the last quarter. V Square Quantitative Management LLC lifted its stake in Insmed by 60.3% in the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 248 shares during the last quarter. Finally, Spire Wealth Management purchased a new position in Insmed in the fourth quarter worth approximately $47,000.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Bank of America lifted their target price on shares of Insmed from $92.00 to $96.00 and gave the stock a “buy” rating in a research note on Thursday, March 20th. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Wells Fargo & Company lifted their price target on shares of Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Stifel Nicolaus dropped their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $100.00 price target on shares of Insmed in a research report on Wednesday, March 19th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and an average target price of $96.73.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.